Cortijo, Julio

The JAK2 pathway is activated in idiopathic pulmonary fibrosis

Milara, J., Hernandez, G., Ballester, B., Morell, A., Roger, I., Montero, P., Escrivá, J., Lloris, J. M., Molina-Molina, M., Morcillo, E., et al. (2018) · Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 188

Angiotensin II Induces Neutrophil Accumulation In Vivo Through Generation and Release of CXC Chemokines

Nabah, Y. N. A., Mateo, T., Estellés, R., Mata, M., Zagorski, J., Sarau, H., Cortijo, J., Morcillo, E. J., Jose, P. J., & Sanz, M.-J. (2004) · Circulation

Chemokine receptors and signalingRenin-Angiotensin System Studies

Cited by 124

Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin‐induced lung injury

Cortijo, J., Iranzo, A., Milara, X., Mata, M., Cerdá‐Nicolás, M., Ruiz‐Saurí, A., Tenor, H., Hatzelmann, A., & Morcillo, E. (2009) · British Journal of Pharmacology

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPhosphodiesterase function and regulation

Cited by 114

Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation

Ballester, B., Milara, J., & Cortijo, J. (2020) · Oncotarget

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisTGF-β signaling in diseases

Cited by 43